Candel therapeutics sets path to success: recent achievements pave the way for a promising 2024 propelled by key value drivers and catalysts

Approaching 6 anticipated data readouts across 3 platforms in 2024, including survival data in non-small cell lung cancer (nsclc) and a potentially registrational phase 3 clinical trial in prostate cancer focusing on strategic key value drivers and catalysts, as a follow up to positive initial clinical and biomarker data in hard-to-treat cancers advancing the immunotherapy field with next-generation investigational therapies at the intersection of advanced analytics, biology and vectorology executing on goal for operational excellence and efficiency, as evidenced by company's recent program prioritization needham, mass., feb. 05, 2024 (globe newswire) -- candel therapeutics, inc. (candel or the company) (nasdaq: cadl), a clinical stage biopharmaceutical company focused on developing multimodal biological immunotherapies to help patients fight cancer, today highlighted recent successes across the company's immunotherapy portfolio and provided updates on multiple upcoming milestones.
CADL Ratings Summary
CADL Quant Ranking